MSD Korea’s antibody, Zerbaxa’s approval in Korea

Published: 2017-04-20 13:35:22

Updated: 2017-04-20 13:35:22

‘Zerbaxa(generic name: ceftolozane+tazobactam),’ a MSD Korea’s(CEO Avi BenShoshan) new antibody, acquired sales approval in Korea. On the 7^th, the Ministry of Food and Drug Safety(MFDS) approved the Zerbaxa’s commercialization as a combination therapy with metronidazole for the treatment of complicated urinary tract and intra-abdominal infection on adult patients.

Zerbaxa, a combination drug w...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.